Live feed08:30:00·6mPRReleasevia QuantisnowDogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026ByQuantisnow·Wall Street's wire, on your screen.DWTX· Dogwood Therapeutics Inc.Health Care
